International Journal of Clinical Oncology

Published in:

17-06-2024 | Prostatectomy | Original Article

Clinical factors predicting the outcome of salvage radiotherapy for patients with biochemical recurrence after radical prostatectomy

Authors: Takeru Fujimoto, Takayuki Goto, Rihito Aizawa, Takashi Ogata, Kiyonao Nakamura, Takayuki Sumiyoshi, Yuki Kita, Kimihiko Masui, Takeshi Sano, Atsuro Sawada, Ryoichi Saito, Shusuke Akamatsu, Takashi Mizowaki, Takashi Kobayashi

Published in: International Journal of Clinical Oncology | Issue 9/2024

Abstract

Background

It remains unclear which patients with biochemical recurrence after prostatectomy are most suitable for salvage radiotherapy. We evaluated the parameters related to outcomes.

Methods

We retrospectively evaluated patients who underwent salvage therapy for biochemical recurrence after prostatectomy between 2005 and 2019. This study aimed to evaluate biochemical recurrence-free survival (bRFS) after salvage radiotherapy and elucidate the parameters associated with bRFS. The bRFS rate was calculated using the Kaplan–Meier method, and the parameters associated with bRFS were evaluated using Cox regression analysis.

Results

This study included 67 patients treated with salvage radiotherapy with a median age of 67 years at salvage radiotherapy. The median follow-up period after salvage radiotherapy was 7.3 years. The 5-year bRFS rate following salvage radiotherapy was 47.1%. Univariate analysis showed that PSA doubling time < 6 months, positive surgical margin, and pathological Gleason score ≥ 8 were significantly associated with shorter bRFS (p < 0.001, p = 0.036, p = 0.047, respectively). Multivariable analysis showed that a PSA doubling time < 6 months and positive surgical margins were significantly associated with shorter bRFS (p = 0.001 and p = 0.018, respectively). No serious adverse events were observed.

Conclusions

In our hospital, approximately half of the patients are under long-term control with salvage radiotherapy. A PSA doubling time of < 6 months and positive surgical margins were suggested to be associated with poor outcomes of salvage radiotherapy.

Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597. https://doi.org/10.1001/jama.281.17.1591CrossRefPubMed

Boorjian SA, Eastham JA, Graefen M et al (2012) A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 61(4):664–675. https://doi.org/10.1016/j.eururo.2011.11.053CrossRefPubMed

Mizowaki T, Aoki M, Nakamura K et al (2015) Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study. J Radiat Res 56(4):750–756. https://doi.org/10.1093/jrr/rrv027CrossRefPubMedPubMedCentral

Kinoshita H, Shimizu Y, Mizowaki T et al (2013) Risk factors predicting the outcome of salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy. Int J Urol 20(8):806–811. https://doi.org/10.1111/iju.12049CrossRefPubMed

Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041. https://doi.org/10.1200/jco.2006.08.9607CrossRefPubMed

Wiegel T, Lohm G, Bottke D et al (2009) Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome–results of a retrospective study. Int J Radiat Oncol Biol Phys 73(4):1009–1016. https://doi.org/10.1016/j.ijrobp.2008.06.1922CrossRefPubMed

Briganti A, Karnes RJ, Joniau S et al (2014) Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 66(3):479–486. https://doi.org/10.1016/j.eururo.2013.11.045CrossRefPubMed

Dasgupta P, Kirby RS (2009) The current status of robot-assisted radical prostatectomy. Asian J Androl 11(1):90–93. https://doi.org/10.1038/aja.2008.11CrossRefPubMed

Sooriakumaran P, Srivastava A, Shariat SF et al (2014) A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol 66(3):450–456. https://doi.org/10.1016/j.eururo.2013.11.018CrossRefPubMed

10.

Cookson MS, Aus G, Burnett AL et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177(2):540–545. https://doi.org/10.1016/j.juro.2006.10.097CrossRefPubMed

11.

Parker CC, Clarke NW, Cook AD et al (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396(10260):1413–1421. https://doi.org/10.1016/s0140-6736(20)31553-1CrossRefPubMed

12.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244CrossRefPubMed

13.

Carrie C, Magné N, Burban-Provost P et al (2019) Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol 20(12):1740–1749. https://doi.org/10.1016/s1470-2045(19)30486-3CrossRefPubMed

14.

Bottke D, de Reijke TM, Bartkowiak D et al (2009) Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer 45(Suppl 1):148–157. https://doi.org/10.1016/s0959-8049(09)70027-9CrossRefPubMed

15.

Ploussard G, Fossati N, Wiegel T et al (2021) Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. Eur Urol Oncol 4(2):150–169. https://doi.org/10.1016/j.euo.2021.01.001CrossRefPubMed

16.

Saika T, Miura N, Fukumoto T et al (2018) Role of robot-assisted radical prostatectomy in locally advanced prostate cancer. Int J Urol 25(1):30–35. https://doi.org/10.1111/iju.13441CrossRefPubMed

17.

Trapasso JG, deKernion JB, Smith RB et al (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152(5 Pt 2):1821–1825. https://doi.org/10.1016/s0022-5347(17)32394-7CrossRefPubMed

18.

Jackson WC, Johnson SB, Li D et al (2013) A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol 8(1):170. https://doi.org/10.1186/1748-717X-8-170CrossRefPubMedPubMedCentral

19.

Arlen PM, Bianco F, Dahut WL et al (2008) Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179(6):2181–2185. https://doi.org/10.1016/j.juro.2008.01.099CrossRefPubMedPubMedCentral

20.

Crawford ED, Koo PJ, Shore N et al (2019) A clinician’s guide to next generation imaging in patients with advanced prostate cancer (RADAR III). J Urol 201(4):682–692. https://doi.org/10.1016/j.juro.2018.05.164CrossRefPubMed

21.

Otani T, Saga T, Ishimori T et al (2022) Detection efficacy of PET/CT with (18)F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Ann Nucl Med 36(3):302–309. https://doi.org/10.1007/s12149-021-01704-6CrossRefPubMed

22.

Meijer D, Eppinga WSC, Mohede RM et al (2022) Prostate-specific membrane antigen positron emission tomography/computed tomography is associated with improved oncological outcome in men treated with salvage radiation therapy for biochemically recurrent prostate cancer. Eur Urol Oncol 5(2):146–152. https://doi.org/10.1016/j.euo.2022.01.001CrossRefPubMed

23.

Kneebone A, Fraser-Browne C, Duchesne GM et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21(10):1331–1340. https://doi.org/10.1016/s1470-2045(20)30456-3CrossRefPubMed

Title: Clinical factors predicting the outcome of salvage radiotherapy for patients with biochemical recurrence after radical prostatectomy
Authors: Takeru Fujimoto
Takayuki Goto
Rihito Aizawa
Takashi Ogata
Kiyonao Nakamura
Takayuki Sumiyoshi
Yuki Kita
Kimihiko Masui
Takeshi Sano
Atsuro Sawada
Ryoichi Saito
Shusuke Akamatsu
Takashi Mizowaki
Takashi Kobayashi
Publication date: 17-06-2024
Publisher: Springer Nature Singapore
Keywords: Prostatectomy
Prostatectomy
Radiotherapy
Published in: International Journal of Clinical Oncology / Issue 9/2024
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-024-02571-7

The miR-199a-5p/HIF1α dual-regulatory axis participates in hypoxia-induced aggressive phenotypes of oral squamous cell carcinoma (OSCC) cells

Oral Cancer
Original Article

Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer

Open Access
Gastric Cancer
Invited Review Article

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort

Checkpoint Inhibitors
Original Article

An evaluation model of hepatic steatosis based on CT value and serum uric acid/HDL cholesterol ratio can predict intrahepatic recurrence of colorectal cancer liver metastasis

Metastasis
Original Article

Comorbid thrombosis as an adverse prognostic factor in patients with ovarian clear cell carcinoma regardless of staging

Thrombosis
Original Article

New therapeutic target molecules for gastric and gastroesophageal junction cancer

Targeted Therapy
Invited Review Article

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Genetic Testing
On-demand Webinar

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:

Illumina, Inc., and Eli Lilly and Company

Dr. Vivek Subbiah

Dr. Alexander Drilon

Dr. Michelle Williams

Developed by: Springer Healthcare

Watch now

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Clinical factors predicting the outcome of salvage radiotherapy for patients with biochemical recurrence after radical prostatectomy